Objective: Inflammation is a process associated with the development and progression of cancer. Desloratadine (DES) and Trimebutin (TMB) are anti-inflammatory agents used in the treatment of various diseases. This study aimed to investigate the antitumor effects of DES and TMB, which exhibit anti-inflammatory effects, on different human cancer cell lines.
Materials and Methods: In this study, human prostate (LNCaP), ovarian (A2780), breast (MCF-7) and colon cancer (Caco-2) cell lines were treated with DES and TMB at concentrations of 1, 5, 25, 50 and 100 µM. Cells were treated with the compounds for 6, 12, and 24 hours, and the change in cell viability was determined using the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay. The inhibitory concentration 50 (LogIC50) values of the compounds were calculated using GraphPad Prism 8 software based on cell viability results. The genotoxic effects of the compounds on cells were determined using the comet assay. Group comparisons were performed using the Kruskal-Wallis H test and p
Key words: Apoptosis; Cancer; Desloratadine; Trimebutin
|
Download PDF 
Post
